Bruehlman Ronald E reported option exercise involving 21,692 shares of GoodRx Holdings, Inc. on Nov 8, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
21,692Class A Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
229,044Direct
Trade date
Nov 8, 2026Option exercise
Filed
Nov 9, 2026, 4:20 PM ET1-day reporting delay
Accession
0001809519-26-000190Code M · Transaction 395919
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 8, 2026Option exercise21,692$0.00$0Trade 395920
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

GDRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GDRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −6%1w ago −4.4%1d ago −3.8%
Returns since7d30d90d180d1y

Footnotes in full

F1: The deferred stock unit award vested as to one-third of the shares underlying the award on November 8, 2026. The deferred stock units will settle on the earliest to occur of the following events (i) December 31, 2029; (ii) Separation from Service; (iii) a Change in Control; (iv) death; or (v) Disability (each, as defined under the GoodRx Holdings, Inc. Deferred Compensation Plan for Directors). F2: Each restricted stock unit represents a contingent right to receive one share of Class A common stock.